SporeGen® was founded by Professor Simon M. Cutting in 2011 originally as Holloway Immunology but has recently taken its new name, SporeGen®. Based at Royal Holloway University of London, SporeGen® has a portfolio of interests focused on the use of bacterial spores.
Our First Agreements
Initial agreements made with partners in Vietnam and India for long term collaboration. Initial investments acquired. Future strategy defined into four areas, vaccines, drug delivery, probiotics and contract research.
Holloway Immunology undertook a name change to SporeGen®. SporeGen® is participating in two EU 7th Framework projects, CaroDel and MariaBox. Licensing deals are in progress with three overseas partners.
SporeGen® utilises their expertise in the field of Bacillus to secure the first of two licencing deals, with BioSpring in Vietnam and Viridis in India. The strains licensed are marketed under the trademarks of HU36® and HU58® which will be used by BioSpring and Viridis to market and develop new probiotics for humans and animals.
SporeGen® begins collaborating on 2 EU funded research grants EMI-TB and Saphir. More Details can be found on our Latest News Tab. SporeGen® are co-coordinating with commercial partners in the development of human and animal probiotic product lines. SporeGen® develop several research projects involving the use of Bacillus.